Preoperative serum α-fetoprotein and prognosis after hepatectomy for hepatocellular carcinoma.

BACKGROUND: While the majority of studies report that a raised serum α-fetoprotein (AFP) level before operation is associated with a high risk of recurrence and death in patients who undergo hepatectomy for hepatocellular carcinoma (HCC), results are conflicting. The aim of this study was to assess the prognostic value of AFP. METHODS: Serum AFP levels were measured in patients with hepatitis-associated HCC who underwent hepatectomy between 1995 and 2012. Kaplan-Meier and multivariable analyses were performed to identify risk factors for overall and disease-free survival. Univariable and multivariable Cox proportional hazards regression was used to evaluate the predictive value of AFP. Receiver operating characteristic (ROC) curves were generated to identify the AFP level that had the highest accuracy in discriminating between survivors and non-survivors. RESULTS: Some 376 patients with hepatitis B virus (HBV)-associated HCC were included in the study. The overall survival rate was 58·8 per cent in patients with an AFP level of 400 ng/ml or less compared with 40·4 per cent for those with a level exceeding 400 ng/ml (P = 0·001). AFP concentration above 400 ng/ml was an independent risk factor for shorter disease-free and overall survival after surgery. ROC analysis indicated that the optimal cut-off values for AFP varied for different subtypes of HCC. The sensitivity and specificity were lower with areas under the ROC curve of less than 0·600. An AFP level greater than 400 ng/ml was not sensitive enough to predict the prognosis in patients with an HCC diameter smaller than 3 cm. CONCLUSION: A serum AFP level above 400 ng/ml predicts poor overall and recurrence-free survival after hepatectomy in patients with HBV-associated HCC. AFP is not a strong prognostic marker given its poor discriminatory power, with low sensitivity and specificity.

Giant hepatocellular adenoma presenting with chronic iron deficiency anemia.

Hepatic adenomas are benign liver tumors found mostly in young women with a history of oral contraceptive usage. They commonly present with abdominal pain from the tumor mass effect, bleeding, or rupture. We report a case of a young woman with a giant hepatic adenoma presenting with chronic iron deficiency anemia, requiring repeated blood transfusion. The mass was an incidental finding with typical features of a hepatic adenoma. Resection was performed and the hemoglobin remained stable up to the present fourth year of follow-up. This is an unusual presentation for which an association is investigated here. There was no evidence of intra-tumoral bleed but reverse-transcribed real-time PCR revealed higher tumor hepcidin RNA expression. Chronic iron deficiency anemia can be an initial presenting problem in patients with hepatic adenomas. Its cause may be multifactorial but the role of hepcidin-mediated anemia needs further evaluation in future cases.